Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly’s Failed Solanezumab: Could It Get Another Chance In A ‘Silicon Valley’ FDA?

25 Jan 2017

• By Ramsey Baghdadi

EraseDementia_1200x675

Related Content

Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking

12 Jan 2017

The Eteplirsen Approval: Former FDA Officials Weigh In On The Science

29 Sep 2016

Lilly’s Thanksgiving Turkey: Lessons From Another Failed Alzheimer’s Program

30 Nov 2016

Related Companies

Eli Lilly and Company

Additional Topics

United States FDA Elections Drug Review Regulation BioPharmaceutical Neurology

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.